Zobrazeno 1 - 10
of 15
pro vyhledávání: ''
Autor:
Magdalena Klanova, Jeffrey M. Venstrom, Marek Trněný, Mikkel Z. Oestergaard, Christian Klein, Umberto Vitolo, Andrea Knapp, Valentin Goede, Tina Nielsen, Robert Marcus, A. Cardona, Deniz Sahin, Wolfgang Hiddemann, Alexandra Bazeos, Laurie H. Sehn, Christopher R. Bolen, Harald Zeuner, Günter Fingerle-Rowson, Nathalie Spielewoy
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(15)
Purpose: Natural killer (NK) cells are key effector cells for anti-CD20 monoclonal antibodies (mAb), such as obinutuzumab and rituximab. We assessed whether low pretreatment NK-cell count (NKCC) in peripheral blood or tumor tissue was associated with
Autor:
Pauline Crooks, Jonathan Ellis, Colm Keane, Kimberley Jones, Clare Gould, Erica Han, Josh Tobin, Simone Birch, Peter Wood, David Hamm, Frank Vari, Maher K. Gandhi, Raymond J. Steptoe, Kim Anh Le-Cao, Sanjiv Jain, Michael R. Green, Dipti Talaulikar
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(7)
Purpose: To investigate the relationship between the intra-tumoral T-cell receptor (TCR) repertoire and the tumor microenvironment (TME) in de novo diffuse large B-cell lymphoma (DLBCL) and the impact of TCR on survival. Experimental Design: We perfo
Autor:
Charles F Levenback, Razelle Kurzrock, John W. Moroney, Gerald S. Falchook, Aung Naing, Jennifer J. Wheler, David S. Hong, Siqing Fu, Stacy L. Moulder, Thorunn Helgason
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 18(20)
Purpose: Preclinical data suggest that combining the mTOR/hypoxia-inducible factor (HIF) inhibitor temsirolimus and the antiangiogenesis antibody bevacizumab may augment antitumor activity as well as resensitize cells to anthracyclines. Experimental
Autor:
German Ott, Lisa M. Rimsza, Javeed Iqbal, Raymond R. Tubbs, Dennis D. Weisenburger, Louis M. Staudt, Rita M. Braziel, Jan Delabie, James R. Cook, James O. Armitage, Julie M. Vose, Randy D. Gascoyne, Nathalie A. Johnson, Timothy C. Greiner, Elaine S. Jaffe, Paul N. Meyer, Lynette M. Smith, Wing C. Chan, Andreas Rosenwald, Joseph M. Connors, Elias Campo
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 17(24)
Purpose: We have previously shown the prognostic significance of BCL2 expression in the activated B-cell–like diffuse large B-cell lymphoma (ABC-DLBCL) patients treated with cyclophosphamide-Adriamycin-vincristine-prednisone (CHOP) or CHOP-like the
Autor:
Sunil Badve, Edith A. Perez, Roberto Bugarini, Joseph A. Sparano, Diana Brassard, George W. Sledge, Steve Rowley, Nancy E. Davidson, Lawrence N. Shulman, Steven Shak, Paraic A. Kenny, Frederick L. Baehner, Robert Gray, Lori J. Goldstein, Silvana Martino, Barrett H. Childs
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 17(22)
Purpose: To conduct an exploratory analysis of the relationship between gene expression and recurrence in patients with operable triple-negative breast cancer (TNBC) treated with adjuvant doxorubicin-containing chemotherapy. Experimental Design: RNA
Autor:
John W. Moroney, Robert L. Coleman, Thorunn Helgason, Aung Naing, Diane C. Bodurka, Stacy L. Moulder, Matthew Schlumbrecht, Filip Janku, David S. Hong, Razelle Kurzrock
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 17(21)
Purpose: Liposomal doxorubicin (D) and bevacizumab (A) are active single agents in gynecologic and breast malignancies which share a resistance mechanism: upregulation of hypoxia inducible factor (HIF-1α). We, therefore, added temsirolimus (T), whic
Autor:
Richard M. Steingart, Maria Theodoulou, Steven Sugarman, Peter G. Cordeiro, Michelle E. Melisko, Chau T. Dang, Theresa Gilewski, Laura Hawks, Monica Morrow, Maura N. Dickler, John W. Park, Jill Grothusen, Qin Zhou, Clifford A. Hudis, Mary Ellen Moynahan, Andrew D. Seidman, Diana Lake, Gabriella D'Andrea, B. Nulsen, Carmen Merali, Heather L. McArthur, Tiffany A. Traina, Jane E. Sealey, Sujata Patil, Mark E. Robson, Hope S. Rugo, Larry Norton, Monica Fornier, Shanu Modi, Nancy Sklarin, Mark M. Moasser, Matthew Paulson, John H. Laragh
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 17(10)
Purpose: Bevacizumab confers benefits in metastatic breast cancer but may be more effective as adjuvant therapy. We evaluated the cardiac safety of bevacizumab plus dose-dense doxorubicin–cyclophosphamide (ddAC) → nanoparticle albumin–bound (na
Autor:
Charles Coutant, Young Chul Kim, Jae K. Lee, Roman Rouzier, Keith A. Baggerly, W. Fraser Symmans, Lajos Pusztai, Yuan Qi, Dan Theodorescu
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 16(2)
Purpose: Several different multivariate prediction models using routine clinical variables or multigene signatures have been proposed to predict pathologic complete response to combination chemotherapy in breast cancer. Our goal was to compare the pe
Autor:
Yusri A. Elsayed, Jean-Yves Blay, Brian L. Samuels, Michael P. Fanucchi, Claudia Lebedinsky, Isabelle Ray-Coquard, Leen Gilles, Margaret von Mehren, Axel Le Cesne, Brigid Buckley
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 14(20)
Purpose: To determine the dose of trabectedin plus doxorubicin with granulocyte colony-stimulating factor support associated with manageable neutropenia and acceptable dose-limiting toxicities (DLT) in patients with recurrent or persistent soft-tissu
Autor:
Ken Herrmann, Tibor Schuster, Hinrich Wieder, Markus Schwaiger, Andreas K. Buck, Marion Schöffel, Tobias Dechow, Falko Fend, Justus Duyster, Hans-Jürgen Wester, Christian Meyer zum Büschenfelde, Christian Peschel, Bernd-Joachim Krause
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 13(12)
Purpose: To evaluate 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography (FLT-PET) for early monitoring response of high-grade non-Hodgkin's lymphoma to treatment with cyclophosphamide-adriamycin-vincristine-prednisone chemotherapy with